Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blocking FcγRIII with anti-CD16 mab (3G8 and GMA161) increases platelets in immune thrombocytopenia: Two pilot studies

View Full Paper
Ask AI
Bookmark
Share

Authors

RKRobert P. KimberlyRNRalph L. NachmanJBJames B. Bussel

Discussion

Loading...

Member takes

Overview

Pilot studies demonstrate monoclonal antibodies raise platelets in chronic immune thrombocytopenia, suggesting new treatment avenues.

Key Points

  • The study aimed to explore the effect of blocking FcγRIII on platelet counts in patients with immune thrombocytopenia (ITP).
  • Two pilot studies were conducted with 21 adults having chronic, refractory ITP.
  • Patients received anti-CD16 monoclonal antibodies 3G8 and GMA161 to evaluate their efficacy.
  • Platelet response was measured as an increase of ≥20 × 10⁹/L within 7 days after infusion.
  • 67% of patients achieved transient platelet responses post anti-CD16 therapy.
  • Platelet counts peaked rapidly after infusion, with mean increases of 159 × 10⁹/L for 3G8 and 121 × 10⁹/L for GMA161.
  • Acute reactions were more severe with 3G8 compared to GMA161, which had improved tolerability.

Cite This Study

Kimberly et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e11chttps://doi.org/10.1182/blood-2025-4821
View Full Paper
Ask AI
Bookmark
Share